¹Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh 11671, SAUDI ARABIA
²Department of Pharmacology & Toxicology, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, EGYPT
³Department of Biological Sciences, Faculty of Science, University of Jeddah, Jeddah 23218, SAUDI ARABIA
⁴Department of Biology, Edge Hill University, Ormskirk L39 4QP, UNITED KINGDOM
⁵Department of Life Sciences, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester M1 5GD, UNITED KINGDOM DOI : 10.9775/kvfd.2025.35289 Acute dyslipidemia is a key contributor to metabolic disturbances, often driven by lipid imbalance, and systemic inflammation. This study explored the potential of reynoutrin, a bioactive flavonoid glycoside, in counteracting lipid abnormalities and their associated oxidative and inflammatory responses in a rat model of acute dyslipidemia. Reynoutrin (25 and 50 mg/kg) was administered orally for 14 days, followed by the induction of acute dyslipidemia using poloxamer-407 (P407). Biochemical analyses included lipid profile assessment, hepatic lipid-regulating enzyme activity, oxidative stress biomarkers, and inflammatory mediators. The HMG-CoA reductase and fatty acid synthase (FAS) inhibitory activities of reynoutrin were determined. P407 administration resulted in marked elevations in plasma cholesterol, triglycerides, vLDL-C, and LDL-C, with reductions in HDL-C and lipoprotein lipase activity. Reynoutrin treatment mitigated these effects, normalized lipid parameters, and downregulated hepatic HMG-CoA reductase and FAS. It also enhanced LDL-R expression. Reynoutrin significantly reduced hepatic malondialdehyde and nitric oxide while boosting antioxidant enzyme levels. Inflammatory cytokines and NF-κB p65 expression were elevated in dyslipidemic rats but significantly attenuated following reynoutrin administration. Reynoutrin exhibited binding affinities with HMG-CoA reductase, LDL-R PCSK9 binding domain, and FAS KS and TE domains. In conclusion, reynoutrin exhibits potent lipid-lowering, antioxidant, and anti-inflammatory properties, potentially via modulation of lipid metabolism, redox balance, and immune signaling in acute dyslipidemia. These findings suggest its therapeutic promise in managing dyslipidemia-associated complications. Keywords : Dyslipidemia, Reynoutrin, Inflammation, Oxidative stress